Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.
Fuji Research Laboratories, Pharmaceutical Division, Kowa Company Limited, 332-1 Ohnoshinden, Fuji, Shizuoka 417-8650, Japan.
Mol Pharm. 2020 Nov 2;17(11):4346-4353. doi: 10.1021/acs.molpharmaceut.0c00764. Epub 2020 Oct 16.
Here, we describe the absorption pathways of nanoparticles whose surface is modified with bile acid and present environmental factors that influence oral bioavailability (BA) from the gastrointestinal tract (GIT). The approach utilized 100 nm sized fluorescence-labeled, carboxylated polystyrene nanoparticles (CPN) conjugated with glycocholic acid (G/CPN) to exclude potential artifacts, if existing, and instability issues in evaluating the transit of G/CPN in the GIT and measuring BA. The study using SK-BR-3 that expresses the apical sodium bile acid transporter showed that once G/CPN is internalized, it stayed 2.9 times longer in the cells than CPN, indirectly suggesting that G/CPN takes intracellular trafficking pathways different from CPN in SK-BR-3 cells. In a Caco-2 cell monolayer, G/CPN passed through the monolayer without damaging the tight junction. G/CPN, when administered orally in rodents, showed sustained transit time in the GIT for at least 4 h and was absorbed into the intestinal lymphatic system and circulated into the blood. Ingestion of food before and after oral administration delays G/CPN absorption and decreases BA. A decrease in gastrointestinal motility by anesthetic condition increased the relative BA of G/CPN by up to 74%. Thus, the oral BA of G/CPN can be optimized by taking food ingestion and gastrointestinal motility into account.
在这里,我们描述了表面修饰有胆汁酸的纳米粒子的吸收途径,并介绍了影响胃肠道(GIT)中口服生物利用度(BA)的环境因素。该方法利用 100nm 大小的荧光标记羧化聚苯乙烯纳米粒子(CPN)与甘胆酸(G/CPN)缀合,以排除在评估 G/CPN 在 GIT 中的转运和测量 BA 时可能存在的潜在假象和不稳定性问题。使用表达顶端钠胆汁酸转运蛋白的 SK-BR-3 的研究表明,一旦 G/CPN 被内化,它在细胞中的停留时间比 CPN 长 2.9 倍,这间接表明 G/CPN 在 SK-BR-3 细胞中采用了不同于 CPN 的细胞内运输途径。在 Caco-2 细胞单层中,G/CPN 穿过单层而不会破坏紧密连接。在啮齿动物中口服给予 G/CPN 时,它在 GIT 中的转运时间至少持续 4 小时,并被吸收到肠淋巴系统并循环到血液中。在口服给药前后摄入食物会延迟 G/CPN 的吸收并降低 BA。麻醉状态下的胃肠道蠕动减少可使 G/CPN 的相对 BA 增加高达 74%。因此,通过考虑食物摄入和胃肠道蠕动,可以优化 G/CPN 的口服 BA。